As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.

The AAM has welcomed reports that US negotiators for the proposed US-Mexico-Canada trade agreement could be willing to soften demands on intellectual-property protections for pharmaceuticals, including the data exclusivity period for biologics.

EU member states are being urged by the European Commission to cooperate more closely on pricing and reimbursement, managed access deals and policies to promote generics and biosimilars.

Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.

Mylan and Biocon have launched their Ogivri trastuzumab biosimilar in the US, marking the second biosimilar rival to Herceptin and leading a new wave of trastuzumab biosimilars expected to arrive in the US early next year.

Stada has struck a deal to acquire the prescription and consumer health businesses of Ukraine’s Biopharma, including local manufacturing operations and around 300 new staff. Biopharma will retain its blood plasma-based business.